Supreme Court Hears Key Case on Pesticide Liability
On April 27, 2026, the U.S. Supreme Court began hearing arguments in a crucial case that could reshape the landscape for lawsuits against pesticide manufacturers regarding health concerns.
The case in question, Monsanto vs. Darnell, revolves around glyphosate, the main ingredient in a herbicide that was initially produced by Monsanto and is now under Bayer’s ownership. Despite Bayer’s claims of safety, multiple scientific studies have associated glyphosate with cancer, leading to numerous lawsuits across the country.
In this instance, Monsanto is appealing a Missouri court’s $1.25 million ruling in favor of John Darnell, who argued the company failed to adequately warn consumers about Roundup’s cancer risks.
If the court rules in favor of Monsanto, it might set a federal precedent that shields the industry from similar liabilities associated with “breach of duty to warn” claims in state courts.
“There’s really no way to look at this case and not understand that a jury in Missouri indicated there should be a cancer warning that the EPA does not mandate,” stated Monsanto attorney Paul Clement. “That seems like an extra requirement beyond what the EPA asks for.”
Conservative Justice Neil Gorsuch questioned the logic behind this, suggesting, “If it’s truly complicated to add such labels without EPA approval, what does it say when the registrant issues cancer warnings independently?” Clement responded that these situations were just “implementation errors.”
Bayer has been facing significant legal challenges over the past ten years, fighting against over 100,000 lawsuits claiming that glyphosate herbicides are responsible for causing non-Hodgkin’s lymphoma.
In the ongoing Darnell case, jurors have frequently found Monsanto guilty of not providing enough warnings about the potential cancer risks associated with glyphosate.
This reflects a growing trend in the judiciary towards holding manufacturers accountable for their labeling practices, despite the company’s persistent challenges to both the scientific evidence and legal arguments in higher courts.
“We believe that the express preemption clause mandates legal uniformity. Missouri law shouldn’t diverge from U.S. law,” commented Darnell’s attorney, Ashley Keller. She emphasized that different juries could arrive at conflicting conclusions—one jury might find Monsanto blameless, while another could agree with Darnell’s perspective.
Bayer’s CEO noted that the settlement and the Supreme Court proceedings are “independently necessary and mutually reinforcing” in the context of managing litigation.
Bill Anderson, Bayer’s CEO, expressed that the proposed class action settlement and the Supreme Court case together create a crucial avenue out of uncertainty regarding ongoing litigation.
